Dual targeting of BCR-ABL1 and IRE1α is a promising therapeutic strategy in Ph+ ALL

ABSTRACT: BCR-ABL positive acute lymphoblastic leukemia (ALL) cell survival is strongly dependent on the IRE1α-XBP1 branch of the Unfolded Protein Response (UPR). In the study at hand, we have focused on exploring the link between BCR-ABL1 and IRE1α to better understand whether a simultaneous pharmacological inhibition of both pathways could represent a beneficial therapeutic strategy in Philadelphia positive (Ph+) ALL. Therefore, the effect on the phosphoproteome of two inhibitors (MKC-8866 and Nilotinib) as well as a combination of both compounds was analysed in this study.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Cell, Cell Culture, Blood

DISEASE(S): Acute Leukemia

SUBMITTER: Christian Preisinger  

LAB HEAD: Iris Appelmann

PROVIDER: PXD012024 | Pride | 2020-09-21

REPOSITORIES: Pride